Most Read Articles
Christina Lau, 13 Feb 2018

Combining gabapentin or pregabalin with opioid analgesics does not significantly improve cancer pain relief compared with opioid monotherapy, according to results of a recent systematic review and meta-analysis.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

Podcast: อายุรศาสตร์ โรคต่อมไร้ท่อมและเมตะบอลิสมโรงพยาบาลพระมงกุฎเกล้า

05 Mar 2020
Podcast: อายุรศาสตร์ โรคต่อมไร้ท่อมและเมตะบอลิสมโรงพยาบาลพระมงกุฎเกล้า
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Thailand digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 13 Feb 2018

Combining gabapentin or pregabalin with opioid analgesics does not significantly improve cancer pain relief compared with opioid monotherapy, according to results of a recent systematic review and meta-analysis.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.